T
Tioga Cardiovascular
Tioga Medical Center Where our patients come first
About Tioga Cardiovascular
Operating from Los Gatos, California, Tioga Cardiovascular functions as a portfolio company of the medical innovation hub Shifamed. The company was co-founded in 2012 by Amr Salahieh and Mike Dineen. Salahieh, the founder of Shifamed, is a seasoned entrepreneur in the medical device sector with a background in biomedical and electrical engineering and a history of creating and exiting successful companies like Sadra Medical and Embolic Protection, Inc. Dineen, who serves as President and CEO, brings over 30 years of MedTech experience, particularly with startups, and has a history of leading Shifamed portfolio companies like Kalila Medical through to acquisition.
Tioga Cardiovascular is focused on the structural heart market, specifically addressing mitral regurgitation (MR), a condition where the mitral valve fails to close properly, affecting millions. The company's core business revolves around the development and eventual commercialization of transcatheter mitral valve replacement (TMVR) systems. This market serves patients who are often too ill to undergo traditional open-heart surgery. Tioga's business model is centered on creating a less invasive, procedurally simpler valve replacement that can be delivered via catheter, aiming for acquisition by a larger medical device company upon reaching key milestones, a model successfully employed by its parent incubator, Shifamed.
The company's primary product under development is the Luna™ TMVR system. This system is designed for transseptal delivery, a less invasive approach to reach the mitral valve. Key features of the Luna™ system include a unique valve and anchor design made from nitinol and a compact delivery profile (28 Fr. ), engineered to minimize obstruction of the left ventricular outflow tract (LVOT) and reduce the number of patients excluded from treatment due to anatomical constraints. The aim is to provide a more adaptable solution for patients with both degenerative and functional MR. Tioga has progressed its technology through multiple funding rounds, including a $15M Series A in 2019, a $30M Series B in 2021, and a $30M Series C in 2023, bringing total funding to over $75M. A significant achievement was the announcement of the first-in-human implantations of the Luna™ system in October 2024.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 58.7/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- medical implants, Cardiology and cardiovascular, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- B2B, B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2025 | $0 | — | Undisclosed | ↗ |
| SERIES COther financing | Feb 2023 | $30M | $120M | PA MedTech VC Fund · The Capital Partnership · AMED Ventures · Shifamed Angels | ↗ |
Growth signals
Latest recorded traffic for Tioga Cardiovascular is 1.4K monthly website visits, up 84.2% over the last three months. Tioga Cardiovascular's team declined 31.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tioga Cardiovascular in the Campbell ecosystem
The Tioga Cardiovascular office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
The Capital Partnership- SHShangby
Cormorant Asset Management
AMED Ventures
Shifamed Angels
Series B and later1 investor entered at this stage
- PFPA MedTech VC Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tioga Cardiovascular on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tioga Cardiovascular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







